Gefitinib is an effective treatment for patients with non-small-cell lung cancer (NSCLC) and mutations in the epidermal growth factor receptor

Author:  

Publisher: Adis International

ISSN: 1173-8324

Source: Inpharma, Vol.1, Iss.1547, 2006-01, pp. : 15-15

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content